Agoracom Blog Home

Posts Tagged ‘investments’

VIDEO – Empower Clinics $CBDT.ca $EPWCF CEO Answers Shareholder Questions In Q&A $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 4:04 PM on Friday, March 5th, 2021

On behalf of Steve and the Empower Clinics team, we are happy to present this Empower Clinics Shareholder Q&A.   

Thanks to all investors that posted their questions here on AGORACOM. 

Enjoy this powerful video.

Empower Clinics $CBDT.ca $EPWCF Announces Locations of First Three Integrated Health Centres in Ontario. Each Location Anticipated to Generate Approximately $3,000,000 In Revenue. Further Locations to Be Announced $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:01 AM on Thursday, February 25th, 2021

Launch Confirms Empower Stated Strategy To Execute National Clinic Expansion Following Canadian Clinics Acquisition And Partnership Announcements in 2021

  • Announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue.
  • Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.

VANCOUVER, BC / February 25, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue. Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.

THREE ONTARIO LOCATIONS AND TWELVE PHYSICIANS COMMITTED TO OPEN

The locations and approximate sizes of the integrated health centres are as follows:

1) Etobicoke, Ontario Approximately 2,700 sq ft.

2) London, Ontario Approximately 3,100 sq ft.

3) Etobicoke, ON (site two) Approximately 2,900 sq ft.

“Dr. Aviv Tsimmerman and Dr. Jordan Rabinowitz are executing on our growth initiatives, they are achieving milestones, they are opening our healthcare centers.” said Steven McAuley, Chairman & CEO. “Our approach is based on patients and their needs, the delivery of care, an improved healthcare model, that provides advanced technology and access for an improved healthcare outcome.”

Each location is expected to host 4-6 physicians. Empower has already secured commitments from twelve (12) physicians to date, with numerous additional medical doctors and para-medical practitioners expressing interest to join the team.

“Having a strategic blend of health professionals allows us to provide an unparalleled integrative healthcare experience.” stated Dr. Jordan Rabinowitz, Chief Operating Officer. He further states, “This defines our path to assist millions of Canadians nationwide.”

HEALTH CARE SERVICES TO BE DELIVERED AND ANTICIPATED REVENUE MODEL

Empower will be opening primary care, plus para-medical healthcare services, with a target of four (4) to six (6) medical doctors and four (4) to six (6) paramedical practitioners per location.

Primary care services include:

  • Family physicians
  • Walk-in physicians
  • Tele-medicine and virtual care

Empower expects to generate $400,000 – $600,000 in annual revenue per MD, per location, which equates to a revenue range between $1,600,000 – $2,400,000 annually per location.

Paramedical services include:

  • Chiropractic
  • Physiotherapy
  • Registered Massage Therapy
  • Chiropody
  • Acupuncturists
  • Osteopaths
  • Nutritionists

Empower expects to generate $960,000 – $1,200,000 in annual revenue per location.

Together, when each location is fully operational, Empower expects to generate $2,560,000 – $3,600,000 in annual revenue per location.

ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED

Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:

  • Dermatology
  • Cardiology

Empower is currently in advanced discussions with potential partners in each of these specialty areas and believes they hold the potential to add significant value to the operations of each healthcare centre.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

Investors:
Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

Read more: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/756054-empower-clinics-announces-locations-of-first-three-integrated-health-centres-in-ontario-each-location-anticipated-to-generate-approximately-3m/messages/2305329#message

VIDEO – As Empower Clinics $CBDT.ca $EPWCF Makes New Highs On Multiple Major Announcements, CEO McAuley Discusses Why $100M Clinic Revenue Is Stage 1 – And Much More Is Coming $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 5:27 PM on Thursday, February 18th, 2021

When we conduct a “Beyond The Press Release” interview, it is always about A press release …. but Empower Clinics has been moving so fast that we sat down with CEO Steve McAuley to discuss these THREE press releases, the explosive growth of the Company and where it is going:

  • Partnership With Rexall To Launch Integrated Health Centres
  • Surpassed 1,000 COVID-19 tests on 1 day for first time ever … 3X Lab Expansion
  • Secured Medical Device Establishment License (MDEL) To Sell KAI Saliva

As usual, Six Sigma Steve McAuley doesn’t disappoint as he confidently and clearly tells investors where Empower Clinics is going next.

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Demonstrates Significant Scientific Capability by Validating its PCR Tests Accurately Detect COVID-19 U.K. and South Africa Variants $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:31 AM on Thursday, February 18th, 2021

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and travel industry

  • Announced KAI Medical Laboratory has validated that its various COVID-19 PCR test products are able to accurately detect the B.1.1.7 (UK variant) & B.1.351 (South African variant)

VANCOUVER BC / February 18, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce our KAI Medical Laboratory (“KAI LAB”) has validated that its various COVID-19 PCR test products are able to accurately detect the B.1.1.7 (UK variant) & B.1.351 (South African variant).

“The Kai Labs motto of Inspire by Science, Built on Integrity is displayed so accurately as the team of molecular scientists took it upon themselves to validate our test protocols against pervasive new COVID-19 variants.” said Steven McAuley, Chairman & CEO. “Leading with science, continuous improvement and a desire to impact healthcare outcomes elevates Kai Labs to a national and international stage. I expect this to be a competitive advantage as we endeavour to sign new global distribution and sales contracts.”

World Health Organization (WHO) Chief Scientist Confirms The U.K. Variant and South African Variants Are a Concern

Dr. Soumya Swaminathan comments “…scientists have now studied this and have found that these variants do tend to spread faster, they’re more transmissible or more infectious. So that’s the worrying part.”

KAI Medical Laboratory Research & Development a key differentiator for the Future

The KAI Lab testing protocol tests for parts of the viral genome that is not affected by the mutations in the spike protein the “S’ gene. In effect, this ensures the active virus in a patient’s RNA genetic sequence can be detected and a correct test result will be provided.

Dr. Soumya Swaminathan indicates “We know that testing, that identifying those who are infectious, that being able to provide them supportive isolation, tracking and contact tracing, and quarantining all the contacts…All of these things together definitely make a difference in bringing down transmission.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755571-empower-clinics-kai-medical-laboratory-demonstrates-significant-scientific-capability-by-validating-its-pcr-tests-accurately-detect-covid-19-u-k/messages/2304168#message

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Surpasses 1,000 COVID-19 Tests in A Day for The First Time Ever. KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1 $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:47 AM on Tuesday, February 16th, 2021

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and travel industry

  • Announced KAI Medical Laboratory (“KAI LAB”) has exceeded 1,000 COVID-19 test units in a single day for the first time.
  • As a result, Empower is announcing that KAI LAB will undergo an even larger expansion in anticipation of projected growth in COVID-19 test requirements in the U.S., Canada and international markets.

VANCOUVER BC / February 16, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce our KAI Medical Laboratory (“KAI LAB”) has exceeded 1,000 COVID-19 test units in a single day for the first time.

As a result, Empower is announcing that KAI LAB will undergo an even larger expansion in anticipation of projected growth in COVID-19 test requirements in the U.S., Canada and international markets.

KAI MEDICAL LABORATORY NOW EXPANDING TO TRIPLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED RAPID TEST GROWTH

KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower (October 2020 – December 2020), with Q4 COVID-19 test units exceeding 6,000 specimens processed, far surpassing the less than 1,000 total monthly units prior to acquisition.

As a result, on January 21st, Empower announced “Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1.” The Company is revising this planned expansion upwards by announcing KAL LAB is now expanding by tripling its current size in anticipation of projected growth in COVID-19 test requirements.

Empower Clinics Chairman & CEO, Steven McAuley stated “Today marks a significant milestone for Empower and our shareholders. When we first acquired KAI Medical Laboratory just over four months ago, it was processing less than 1,000 specimens monthly up to that point. Today, we are announcing that KAI has surpassed 1,000 units in a day for the first time ever. This is a credit to both Yoshi Tyler, President KAI LAB and her fantastic team, supported by our business development and marketing strategies which, quite frankly, are still in an early phase. We are just getting started.”

For the purposes of facilitating the expansion, Empower has secured additional space adjacent to KAI LAB in order to separate the lab & science from logistics, admin and customer support. Materials handling staff are being added in anticipation of processing the intake of thousands of packages per day.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755396-empower-clinics-kai-medical-laboratory-surpasses-1-000-covid-19-tests-in-a-day-for-the-first-time-ever-kai-laboratory-now-tripling-in-size/messages/2303796#message

Empower Clinics $CBDT.ca $EPWCF Secures Medical Device Establishment Licence (MDEL) Status To Sell KAI Saliva COVID-19 PCR Test Kits In Canada $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:05 AM on Wednesday, February 10th, 2021
  • Announced it has secured Medical Device Establishment Licence (“MDEL”) status to sell its KAI Medical COVID-19 Saliva Test kits (“KAI Saliva”).
  • KAI Saliva is FDA EUA approved for use, has CE Mark and the saliva specimen collection device is approved by Health Canada.
  • KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into to Canada or arriving to other countries that have similar executive travel orders.

VANCOUVER BC / February 10, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce it has secured Medical Device Establishment Licence (“MDEL”) status to sell its KAI Medical COVID-19 Saliva Test kits (“KAI Saliva”).

KAI Saliva is FDA EUA approved for use, has CE Mark and the saliva specimen collection device is approved by Health Canada. KAI Saliva provides travellers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into to Canada or arriving to other countries that have similar executive travel orders.

EMPOWER ACCELERATES ABILITY TO DISTRIBUTE AND SELL MEDICAL DEVICE PRODUCTS IN CANADA THROUGH PARTNERSHIP WITH MEDIPRO CANADA

Empower previously announced the filing of an MDEL application for the purpose of importing, distributing and selling KAI Saliva, which has experienced success upon its launch.

To accelerate the process, Empower partnered with MediPro Canada Inc. (“MediPro”) to utilize their approved MDEL status. MediPro provides healthcare products for governments, large corporations and medical facilities around the world and is led by Hon. Sheila Maureen Copps PC OC.

“We continue to see extensive demand for novel COVID-19 testing products in both private sector and public sector markets throughout North America, Mexico and Caribbean countries.” said Hon. Sheila Copps OC, Partner MediPro Canada. “Leveraging the vast network of MediPro Canada with the integrated healthcare capabilities of Empower Clinics and their novel COVID-19 testing products, makes for an ideal partnership.”

“We all have an urgent requirement for a home-based, self-administered COVID-19 saliva test kit that can help open up the economy and facilitate travel that meets the requirements of the executive travel orders.” said Steven McAuley, Chairman & CEO. “We also must utilize our resources, our reach, our capability, do everything we can to assist, be humanitarians, use our voice, strive to provide improved healthcare, and lead the path of progressive healthcare.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755072-empower-clinics-secures-medical-device-establishment-licence-mdel-status-to-sell-kai-saliva-covid-19-pcr-test-kits-in-canada/messages/2303015#message

Empower $CBDT.ca $EPWCF Partners with #Rexall $MCK To Launch Integrated Healthcare Centres $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 12:26 PM on Tuesday, February 9th, 2021

Partnership Accelerates Empower’s Strategy To Execute National Healthcare Centre Expansion By Bringing Accessible and Progressive Primary Care and Para-Medical Care to Millions of Canadians

  • Announced effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada.
  • Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

VANCOUVER, BC / February 9, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce effective February 8, 2021 a partnership with Rexall Pharmacy Group to launch the first of multiple integrated healthcare centres within Rexall pharmacies commencing in Ontario, Canada.

“In our first press release of 2021 announcing the closing of our Canadian Clinics acquisition, I stated Empower had a winning business model with immediate expansion plans throughout Greater Toronto, followed by Ontario and then nationwide with at least 30 clinics in rapid succession. Empower is proud to begin delivering on that promise.” said Steven McAuley, Chairman & CEO. “To say this is the Company’s biggest announcement in its history would not be an over statement. This partnership with Rexall accelerates our nationwide healthcare expansion strategy, I look forward to bringing Six Sigma philosophies and continuous process improvements to our operations to ensure customers and our patients have access to our primary care and para-medical services for years to come. Today marks a major win for Canadian healthcare and the shareholders of Empower Clinics.”

PARTNERSHIP IDENTIFIES INITIAL LOCATIONS IN ONTARIO

Rexall and Empower have identified numerous initial locations throughout Ontario, spanning from Ottawa to London and around the GTA. The size of the locations can range from 1,500 to 4,000 square feet. As each new location is agreed upon, key terms are outlined in a letter of intent and in the lease or sub-lease agreements with the first anticipated agreements February 2021.

HEALTH CARE SERVICES TO BE DELIVERED

Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

Primary care services include:

  • Family physicians
  • Walk-in physicians
  • Tele-medicine and virtual care

Paramedical services include:

  • Chiropractic
  • Physiotherapy
  • Registered Massage Therapy
  • Chiropody
  • Acupuncturists
  • Osteopaths
  • Nutritionists

ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED

Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:

  • Dermatology
  • Cardiology

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/754999-empower-partners-with-rexall-r-to-launch-integrated-healthcare-centres/messages/2302856#message

CardioComm Solutions $EKG Expands ISO Clearance to Include Multiple Biosign Monitoring Device Integrations in Support of Remote Patient Monitoring Markets $WELL.ca $PRN.ca $VMD.ca $VHI.ca

Posted by AGORACOM-JC at 8:28 AM on Tuesday, February 9th, 2021

New ISO 13485:2016 MDSAP scope paves the way to integration of novel and multiple bio sign monitoring devices for broader patient monitoring solution sales to the consumer and Rx markets globally

  • Received approval on an expanded ISO 13485:2016 (“ISO“) certification in compliance with the Medical Device Single Audit Program (“MDSAP“) for Canada and the United States, to include pulse oximetry (“PO2“), blood pressure (“BP“), weight and temperature in addition to ECG monitoring hardware and software solutions.
  • As remote patient monitoring needs continue to grow so does a need for credible data to be collected from people outside of a hospital or medical office.

Toronto, Ontario–(February 9, 2021) – CardioComm Solutions, Inc. (TSXV: EKG) (“CardioComm” or the “Company“), a leading global provider of consumer heart monitoring and electrocardiogram (“ECG“) acquisition and management software solutions, has received approval on an expanded ISO 13485:2016 (“ISO“) certification in compliance with the Medical Device Single Audit Program (“MDSAP“) for Canada and the United States, to include pulse oximetry (“PO2“), blood pressure (“BP“), weight and temperature in addition to ECG monitoring hardware and software solutions.

As remote patient monitoring needs continue to grow so does a need for credible data to be collected from people outside of a hospital or medical office. “The expansion of virtual health care is here to stay. Accordingly, many patients are using vital sign/bio sign devices at home for measurements of heart rate, temperature, blood pressure and oxygen saturation. Having easy to use accurate devices is a crucial part of safe virtual care. As an emergency physician I frequently see unnecessary ED visits and “near misses” at home due to inaccurate readings from many popular bio sign devices in current use,” states Dr John Foote, Mount Sinai Hospital Director, Emergency Medicine/Family Medicine Residency Program, Assistant Professor, DFCM, The University of Toronto and a member of the Company’s medical advisory committee.

In addition to providing highly accurate consumer and outpatient ECG monitoring capabilities, the Company has been approached to develop solutions to ensure more traditional measurements are monitored with equal accuracy. To meet these requests, CardioComm’s expanded ISO MDSAP certification scope will allow the Company to develop integrations with one or many devices that can each, or configured as a set of devices, monitor ECGs as well as any other bio signal of interest. Adding PO2, BP and temperature specifically will address 2021 new device integration and product development roadmap plans for the Company including those to be used for COVID-19 related health monitoring.

Since securing its ISO MDSAP certification in 2018, CardioComm has assisted medical device makers to have access for the sale of their medical devices in Canada by placing non-MDSAP ISO-certified devices under the Company’s own MDSAP certification. This has resulted in CardioComm becoming a preferred importer, distributor and reseller of hospital and consumer ECG medical devices for organizations based outside of Canada who do not hold their own ISO certifications under the Canada mandated MDSAP designation. For organizations looking to sell into the US, while ISO under MDSAP is not required for sales into the USA, CardioComm’s Canadian/USA MDSAP certification is accepted by the FDA and removes the need for routine FDA inspections where the registered manufacturer, such as CardioComm, is located in Canada.

The Company will provide additional updates related to multiple bio signal monitoring device integrations and adding new capabilities to its remote patient monitoring technologies.

To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations including those with multiple bio sign monitoring capabilities, please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.

Read More: https://agoracom.com/ir/CardioCommSolutions/forums/discussion/topics/754966-cardiocomm-solutions-expands-iso-clearance-to-include-multiple-biosign-monitoring-device-integrations-in-support-of-remote-patient-monitoring-markets/messages/2302805#message

Datametrex AI $DM.ca $DTMXF Tracks Social Media Data to Understand “Reddit” Effect $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 8:16 AM on Thursday, February 4th, 2021
  • Announced that NexaSMART allows for deepened analysis and understanding of social media influence over stock prices.
  • Nexalogy will soon add Reddit and other data sources in order to expand AI interpretation of such trends.
  • NexaSMART stands for “Social Media Automated Reporting Technology.”

Toronto, Ontario–(February 4, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that NexaSMART allows for deepened analysis and understanding of social media influence over stock prices. Nexalogy will soon add Reddit and other data sources in order to expand AI interpretation of such trends. NexaSMART stands for “Social Media Automated Reporting Technology.”

Many investor eyes have turned to the subject of discussion forums such as Reddit that can have impact on the stock market and the price rise of specific stocks, sometimes even despite poor business indicators. According to the Wall Street Journal, mainstream journalists have linked cryptocurrency, stock speculation and conspiracy theories together as a formula for volatility in markets.1

In todays environment, investors rely even more on their investments to secure a comfortable retirement. We believe it is vital for people to know what the truth is and what is fiction when searching for information online that can have a major impact on their returns.

Nexalogy, the wholly owned subsidiary of Datametrex AI Limited, has expertise in disinformation research, and is able to track phenomenon of this nature as evidenced in NexaSMART reports (Read Report Here).

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/754635-datametrex-ai-tracks-social-media-data-to-understand-reddit-effect/messages/2301971#message

Datametrex $DM.ca $DTMXF Announces Investor Webinar $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 1:52 PM on Wednesday, February 3rd, 2021

Toronto, Ontario–(February 3, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that senior management will be hosting an investor update webinar on Tuesday, February 9, 2021, at 1:30 p.m. EST for a corporate update on the latest developments of the Artificial Intelligence technologies and COVID-19 test kits.

Webinar Details:

Date: Tuesday, February 9, 2021

Time: 1:30 p.m. ET

Registration Link: https://us02web.zoom.us/webinar/register/WN_Ge6setHBRAyeBLbKaUIUHQ

Datametrex plans to answer questions previously sent to [email protected] and during the webinar, at management’s discretion and subject to time constraints.

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/754580-datametrex-announces-investor-webinar/messages/2301880#message